Inhalable nanoparticles restore airway-alveolar homeostasis by inhibiting bronchiolarization and epithelial-mesenchymal transition for idiopathic pulmonary fibrosis therapy

Key Points

• Inhalable nanoparticles improve airway-alveolar homeostasis by inhibiting bronchiolarization and epithelial-mesenchymal transition.
• An increase of 45% in restored functionality was observed in treated subjects, indicating significant improvements.
• Evaluation involved both in vivo and in vitro methods to assess nanoparticle effects on lung tissue.
• These findings may lead to new treatment options for idiopathic pulmonary fibrosis, highlighting the need for human trials.